Glox Therapeutics awarded grant to accelerate development of precision antibiotics
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy).